Head to head: tirzepatide beat semaglutide on weight loss

SURMOUNT-5 compared both peptides directly in 751 adults with obesity without diabetes over 72 weeks.

SURMOUNT-5 was a phase 3b trial that compared tirzepatide directly with semaglutide, something rare between molecules of the same family. It enrolled 751 adults with obesity without type 2 diabetes.

At 72 weeks, tirzepatide was superior in percentage weight lost and in the share of people reaching 10, 15, 20 and 25% reductions. Several cardiometabolic risk factors also improved more.

In three points

Direct comparison of two peptides, phase 3b
751 adults with obesity, 72 weeks
Tirzepatide superior at every weight-loss threshold

Compounds mentioned

Tirzepatide Semaglutide

Original source: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.